0 12 IL-2-induced il-2-induced JJ 13 19 growth growth NN 20 22 of of IN 23 27 CD8+ cd8+ JJ 28 29 T t NN 30 34 cell cell NN 35 49 prolymphocytic prolymphocytic JJ 50 58 leukemia leukemia NN 59 64 cells cell NNS 65 73 mediated mediate VBN 74 76 by by IN 77 86 NF-kappaB NF-kappaB NNP 87 96 induction induction NN 97 100 and and CC 101 105 IL-2 il-2 NN 106 114 receptor receptor NN 115 120 alpha alpha NN 121 131 expression expression NN 131 132 . . . 134 137 The the DT 138 145 binding binding NN 146 148 of of IN 149 162 interleukin-2 interleukin-2 NN 163 164 ( ( ( 164 168 IL-2 il-2 NN 168 169 ) ) ) 170 172 to to TO 173 176 its its PRP$ 177 185 receptor receptor NN 186 188 on on IN 189 195 normal normal JJ 196 197 T t NN 198 203 cells cell NNS 204 211 induces induce VBZ 212 219 nuclear nuclear JJ 220 230 expression expression NN 231 233 of of IN 234 241 nuclear nuclear JJ 242 248 factor factor NN 249 255 kappaB kappaB NNP 256 257 ( ( ( 257 266 NF-kappaB NF-kappaB NNP 266 267 ) ) ) 267 268 , , , 269 279 activation activation NN 280 282 of of IN 283 286 the the DT 287 291 IL-2 il-2 NN 292 300 receptor receptor NN 301 302 ( ( ( 302 307 IL-2R IL-2R NNP 307 308 ) ) ) 309 314 alpha alpha NN 315 320 chain chain NN 321 325 gene gene NN 325 326 , , , 327 330 and and CC 331 335 cell cell NN 336 349 proliferation proliferation NN 349 350 . . . 351 353 In in IN 354 357 the the DT 358 365 present present JJ 366 371 study study NN 371 372 , , , 373 376 the the DT 377 381 role role NN 382 384 of of IN 385 390 IL-2R IL-2R NNP 391 400 signaling signaling NN 401 403 in in IN 404 407 the the DT 408 414 growth growth NN 415 417 of of IN 418 422 CD8+ cd8+ JJ 423 424 T t NN 425 429 cell cell NN 430 444 prolymphocytic prolymphocytic JJ 445 453 leukemia leukemia NN 454 455 ( ( ( 455 460 T-PLL T-PLL NNP 460 461 ) ) ) 462 467 cells cell NNS 468 471 has have VBZ 472 476 been be VBN 477 489 investigated investigate VBN 489 490 . . . 491 495 Flow Flow NNP 496 505 cytometry cytometry NN 506 514 revealed reveal VBD 515 519 that that IN 520 527 primary primary JJ 528 536 leukemia leukemia NN 537 542 cells cell NNS 543 547 from from IN 548 549 a a DT 550 557 patient patient NN 558 562 with with IN 563 567 CD8+ cd8+ JJ 568 573 T-PLL T-PLL NNP 574 583 expressed express VBD 584 594 IL-2Ralpha IL-2Ralpha NNP 595 598 and and CC 599 603 beta beta NN 604 610 chains chain NNS 610 611 , , , 612 615 and and CC 616 619 the the DT 620 625 cells cell NNS 626 632 showed show VBD 633 634 a a DT 635 648 proliferative proliferative JJ 649 657 response response NN 658 661 and and CC 662 664 an an DT 665 673 increase increase NN 674 676 in in IN 677 687 IL-2Ralpha IL-2Ralpha NNP 688 698 expression expression NN 699 701 on on IN 702 709 culture culture NN 710 714 with with IN 715 725 exogeneous exogeneous JJ 726 730 IL-2 il-2 NN 730 731 . . . 732 740 Northern Northern NNP 741 745 blot blot NN 746 754 analysis analysis NN 755 761 failed fail VBD 762 764 to to TO 765 771 detect detect VB 772 776 IL-2 il-2 NN 777 781 mRNA mRNA NNP 781 782 , , , 783 793 suggesting suggest VBG 794 798 that that IN 799 803 IL-2 il-2 NN 804 807 may may MD 808 811 act act VB 812 814 in in IN 815 816 a a DT 817 826 paracrine paracrine JJ 827 833 manner manner NN 834 836 in in FW 837 841 vivo vivo FW 841 842 . . . 843 858 Electrophoretic electrophoretic JJ 859 873 mobility-shift mobility-shift JJ 874 880 assays assay NNS 881 889 revealed reveal VBD 890 894 that that IN 895 906 recombinant recombinant JJ 907 911 IL-2 il-2 NN 912 921 increased increase VBD 922 931 NF-kappaB NF-kappaB NNP 932 939 binding binding NN 940 948 activity activity NN 949 951 in in IN 952 959 nuclear nuclear JJ 960 968 extracts extract NNS 969 971 of of IN 972 975 the the DT 976 984 leukemia leukemia NN 985 990 cells cell NNS 990 991 , , , 992 995 and and CC 996 1004 Northern northern NN 1005 1009 blot blot NN 1010 1018 analysis analysis NN 1019 1025 showed show VBD 1026 1030 that that IN 1031 1035 IL-2 il-2 NN 1036 1045 increased increase VBD 1046 1049 the the DT 1050 1059 abundance abundance NN 1060 1062 of of IN 1063 1068 mRNAs mrna NNS 1069 1077 encoding encode VBG 1078 1081 the the DT 1082 1091 NF-kappaB NF-kappaB NNP 1092 1102 components component NNS 1103 1108 c-Rel c-rel NN 1109 1112 and and CC 1113 1117 KBF1 kbf1 NN 1118 1120 in in IN 1121 1126 these these DT 1127 1132 cells cell NNS 1132 1133 . . . 1134 1138 IL-2 il-2 NN 1139 1146 binding binding NN 1147 1155 analysis analysis NN 1156 1168 demonstrated demonstrate VBD 1169 1173 that that IN 1174 1178 IL-2 il-2 NN 1179 1187 markedly markedly RB 1188 1197 increased increase VBD 1198 1201 the the DT 1202 1208 number number NN 1209 1211 of of IN 1212 1215 low low JJ 1216 1224 affinity affinity NN 1225 1231 IL-2Rs il-2r NNS 1232 1234 on on IN 1235 1238 the the DT 1239 1247 leukemia leukemia NN 1248 1253 cells cell NNS 1253 1254 , , , 1255 1262 without without IN 1263 1265 an an DT 1266 1272 effect effect NN 1273 1275 on on IN 1276 1279 the the DT 1280 1286 number number NN 1287 1289 of of IN 1290 1303 high-affinity high-affinity JJ 1304 1310 IL-2Rs il-2r NNS 1310 1311 . . . 1312 1317 These these DT 1318 1325 results result NNS 1326 1330 show show VBP 1331 1335 that that IN 1336 1340 IL-2 il-2 NN 1341 1343 is be VBZ 1344 1351 capable capable JJ 1352 1354 of of IN 1355 1363 inducing induce VBG 1364 1367 the the DT 1368 1375 nuclear nuclear JJ 1376 1386 expression expression NN 1387 1389 of of IN 1390 1399 NF-kappaB NF-kappaB NNP 1400 1402 in in IN 1403 1410 primary primary JJ 1411 1415 CD8+ cd8+ JJ 1416 1421 T-PLL t-pll NN 1422 1427 cells cell NNS 1427 1428 , , , 1429 1432 and and CC 1433 1437 that that IN 1438 1442 this this DT 1443 1449 effect effect NN 1450 1452 is be VBZ 1453 1461 mediated mediate VBN 1461 1462 , , , 1463 1465 at at IN 1466 1471 least least JJS 1472 1474 in in IN 1475 1479 part part NN 1479 1480 , , , 1481 1483 at at IN 1484 1485 a a DT 1486 1502 pretranslational pretranslational JJ 1503 1508 level level NN 1508 1509 . . .